Key result
Fetuin-A shows potential to improve conventional biomarker models for predicting HFpEF occurrence.
Why the study?
Heart failure remains a major health problem with high mortality and morbidity, and current biomarkers have limitations in predicting and stratifying patients at higher risk of HF.
May support novel HF biomarkers for risk stratification; leaves open clinical utility pending prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2021) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Fetuin-A was evaluated. Fetuin-A is a multifaceted biomarker closely associated with cardiovascular disease that shows potential to improve conventional biomarker models for predicting HFpEF occurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: